🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Stifel sustains Lexeo Therapeutics shares target amid encouraging FA-CM trial outcomes

EditorEmilio Ghigini
Published 15/07/2024, 13:20
LXEO
-

On Monday, Stifel reiterated its Buy rating on Lexeo Therapeutics (NASDAQ:LXEO) with a steadfast price target of $20.00 for the shares. The firm's endorsement comes after reviewing data related to LX2006 for the treatment of Friedreich's Ataxia cardiomyopathy (FA-CM), noting a significant reduction in left ventricular mass index (LVMI) among patients who had elevated levels at the outset of the study.

The report highlighted that most FA-CM patients with high baseline LVMI experienced clinically significant reductions in this measure. The firm had previously determined that a reduction of approximately 10% would be considered clinically relevant.

Additionally, Lexeo Therapeutics disclosed that all patients with 12 months of data showed a reduction of more than 50% in troponin levels, a biomarker indicative of cardiac damage or dysfunction.

While the data reveals promising results, the report also pointed to unanswered questions, particularly regarding the regulatory pathway for approval by the FDA and EMA. The determination of whether LVMI, troponin, and other tests will be accepted as useful biomarkers for regulatory approval remains a point of focus.

Moreover, the safety profile of LX2006 was described as unremarkable based on the press release, which is viewed positively. The company is also advancing its clinical trials, already administering doses to patients in Cohort 3, signaling continued progress in its research and development efforts.

Stifel's commentary reflects a cautious optimism for Lexeo's potential in providing a treatment for FA-CM, with an eye towards the future regulatory decisions that will be pivotal for the drug's commercial success.

In other recent news, Lexeo Therapeutics has made significant strides in its ongoing clinical trials and corporate activities. The company's gene therapy candidate, LX2006, has shown promising outcomes in treating Friedreich ataxia (FA) cardiomyopathy, a rare heart condition with no approved therapies.

Interim data from the SUNRISE-FA Phase 1/2 clinical trial and a Weill Cornell Medicine investigator-initiated Phase 1A trial have shown significant improvements in cardiac biomarkers.

The company has also reported progress in its corporate activities. At its 2024 Annual Meeting of Stockholders, Mette Kirstine Agger was elected as a Class I Director, and KPMG LLP was ratified as Lexeo's independent auditor. In addition, Lexeo secured an in-license agreement with Cornell University to bolster the development of LX2006.

Baird has initiated coverage on Lexeo, assigning the stock an Outperform rating. The firm highlighted Lexeo's strategic approach to addressing rare cardiac diseases and Alzheimer's through its advanced gene therapies.

Lexeo's LX2006 has also received Fast Track designation from the U.S. Food and Drug Administration, a status designed to expedite the development and review of drugs that treat severe conditions and address unmet medical needs. These are all recent developments in Lexeo's efforts to address significant unmet medical needs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.